PT3321262T - Inibidores de serina/treonina quinases - Google Patents

Inibidores de serina/treonina quinases

Info

Publication number: PT3321262T
Authority: PT; Portugal
Prior art keywords: serine; kinase inhibitors; threonine kinase; threonine; inhibitors
Prior art date: 2012-03-01

Application number

PT172071235T

Other languages

English (en)

Original Assignee

Array Biopharma Inc

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-01

Filing date

2013-03-01

Publication date

2021-03-04

2013-03-01 Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc

2021-03-04 Publication of PT3321262T publication Critical patent/PT3321262T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

PT172071235T 2012-03-01 2013-03-01 Inibidores de serina/treonina quinases PT3321262T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261605523P	2012-03-01	2012-03-01

Publications (1)

Publication Number	Publication Date
PT3321262T true PT3321262T (pt)	2021-03-04

Family

ID=47892024

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT172071235T PT3321262T (pt)	2012-03-01	2013-03-01	Inibidores de serina/treonina quinases
PT137102224T PT2820009T (pt)	2012-03-01	2013-03-01	Inibidores de serina/treonina quinases

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT137102224T PT2820009T (pt)	2012-03-01	2013-03-01	Inibidores de serina/treonina quinases

Country Status (36)

Country	Link
US (4)	US8697715B2 (pt)
EP (2)	EP3321262B1 (pt)
JP (2)	JP6068515B2 (pt)
KR (1)	KR102093526B1 (pt)
CN (2)	CN106349217B (pt)
AR (2)	AR090220A1 (pt)
AU (1)	AU2013225737B2 (pt)
BR (1)	BR112014021634B1 (pt)
CA (1)	CA2866086C (pt)
CL (1)	CL2014002301A1 (pt)
CO (1)	CO7081155A2 (pt)
CR (1)	CR20140413A (pt)
CY (1)	CY1120172T1 (pt)
DK (2)	DK3321262T3 (pt)
ES (2)	ES2665073T3 (pt)
HK (3)	HK1204323A1 (pt)
HR (2)	HRP20180591T1 (pt)
HU (2)	HUE053994T2 (pt)
IL (2)	IL234376A (pt)
LT (2)	LT3321262T (pt)
MX (1)	MX354675B (pt)
MY (1)	MY191936A (pt)
NO (1)	NO2945854T3 (pt)
NZ (1)	NZ700314A (pt)
PE (1)	PE20150666A1 (pt)
PH (3)	PH12015501653A1 (pt)
PL (2)	PL3321262T3 (pt)
PT (2)	PT3321262T (pt)
RS (2)	RS61500B1 (pt)
RU (1)	RU2650501C2 (pt)
SG (1)	SG11201405356QA (pt)
SI (2)	SI3321262T1 (pt)
TW (1)	TWI589569B (pt)
UA (1)	UA116774C2 (pt)
WO (1)	WO2013130976A1 (pt)
ZA (2)	ZA201406688B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2543050T3 (es)	2011-02-28	2015-08-14	Array Biopharma, Inc.	Inhibidores de serina/treonina quinasa
US9187462B2 (en)	2011-08-04	2015-11-17	Array Biopharma Inc.	Substituted quinazolines as serine/threonine kinase inhibitors
AU2013225737B2 (en) *	2012-03-01	2018-03-01	Array Biopharma Inc.	Serine/threonine kinase inhibitors
BR112014026952B1 (pt) *	2012-05-03	2022-03-15	Genentech, Inc	Derivados de aminopirimidina pirazol e composição que os compreende
KR20150047597A (ko)	2012-08-27	2015-05-04	어레이 바이오파마 인크.	과증식성 질환의 치료를 위한 세린/트레오닌 키나아제 억제제
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
JP2015533151A (ja)	2012-10-16	2015-11-19	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	セリン／スレオニンキナーゼ阻害剤
WO2017156493A1 (en)	2016-03-11	2017-09-14	Denali Therapeutics Inc.	Compounds, compositions, and methods
US9532987B2 (en)	2013-09-05	2017-01-03	Genentech, Inc.	Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
EA032754B1 (ru)	2013-11-01	2019-07-31	Новартис Аг	Аминогетероарил бензамиды в качестве ингибиторов киназы
MY176049A (en) *	2013-12-06	2020-07-22	Genentech Inc	Serine/threonine kinase inhibitors
MX2016008624A (es) *	2013-12-30	2017-01-06	Genentech Inc	Inhibidores de serina/treonina cinasa.
MX370906B (es)	2013-12-30	2020-01-09	Genentech Inc	Inhibidores de serina/treonina cinasa.
CN110452216B (zh)	2014-04-02	2022-08-26	英特穆恩公司	抗纤维化吡啶酮类
RU2684102C2 (ru) *	2014-04-09	2019-04-04	Дженентек, Инк.	Способ получения лекарственных средств
ES2700200T3 (es)	2014-12-22	2019-02-14	Lilly Co Eli	Inhibidores de ERK
TWI704151B (zh)	2014-12-22	2020-09-11	美商美國禮來大藥廠	Ｅｒｋ抑制劑
CA2987963C (en) *	2015-06-03	2023-01-24	Js Innopharm (Shanghai) Ltd.	Heterocyclic compounds for treating psoriasis
US10479791B2 (en) *	2015-06-03	2019-11-19	Changzhou Jiekai Pharmatech Co. Ltd	Heterocyclic compounds as ERK inhibitors
AU2016341520C1 (en)	2015-10-21	2021-07-22	Otsuka Pharmaceutical Co., Ltd.	Benzolactam compounds as protein kinase inhibitors
WO2017070708A1 (en) *	2015-10-23	2017-04-27	Array Biopharma, Inc.	2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
SG11201803066VA (en)	2015-11-09	2018-05-30	Astrazeneca Ab	Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
WO2017087905A1 (en)	2015-11-20	2017-05-26	Denali Therapeutics Inc.	Compound, compositions, and methods
CA3018406A1 (en)	2016-04-15	2017-10-19	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
IL299412A (en)	2016-06-16	2023-02-01	Denali Therapeutics Inc	Pyrimidine-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
GB201706327D0 (en)	2017-04-20	2017-06-07	Otsuka Pharma Co Ltd	A pharmaceutical compound
EP3672973A4 (en) *	2017-08-22	2021-05-26	JS Innopharm (Shanghai) Ltd.	HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
JP2020532982A (ja)	2017-09-08	2020-11-19	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	がんの診断及び治療方法
CA3081651A1 (en)	2017-11-24	2019-05-31	Novartis Ag	Pyridinone derivatives and their use as selective alk-2 inhibitors
EP3750880B1 (en) *	2018-02-08	2022-12-21	Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.	Pyrazine-2(1h)-ketone compound acting as fgfr inhibitor
EP3752200A1 (en)	2018-02-13	2020-12-23	Vib Vzw	Targeting minimal residual disease in cancer with rxr antagonists
SG11202011513RA (en) *	2018-05-22	2020-12-30	Js Innomed Holdings Ltd	Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
WO2020192750A1 (zh) *	2019-03-28	2020-10-01	江苏恒瑞医药股份有限公司	噻吩并杂环类衍生物、其制备方法及其在医药上的应用
WO2020228817A1 (zh) *	2019-05-15	2020-11-19	南京明德新药研发有限公司	Erk抑制剂及其应用
CN114206883A (zh)	2019-08-02	2022-03-18	伟迈可生物有限公司	氧代吡啶稠环衍生物及包含该衍生物的药物组合物
WO2022100586A1 (zh) *	2020-11-11	2022-05-19	南京明德新药研发有限公司	一种含氧杂环丁烷的螺环类化合物的晶型、制备方法及其应用
CN115413669B (zh) *	2022-06-14	2024-03-15	湖南大学	激酶抑制剂及其组合剂在提高植物青枯病抗性中的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU693475B2 (en)	1993-10-01	1998-07-02	Novartis Ag	Pyrimidineamine derivatives and processes for the preparation thereof
EP0672042B1 (en)	1993-10-01	2006-05-03	Novartis AG	Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
CA2274093C (en)	1996-12-05	2006-11-07	Amgen Inc.	Substituted pyrimidinone and pyridinone compounds and their use
US6602872B1 (en) *	1999-12-13	2003-08-05	Merck & Co., Inc.	Substituted pyridazines having cytokine inhibitory activity
CA2398274C (en)	2000-02-25	2009-09-22	F. Hoffmann-La Roche Ag	Adenosine receptor modulators
AU2001252606B2 (en)	2000-04-26	2005-07-07	Eisai R&D Management Co., Ltd.	Medicinal compositions promoting bowel movement
US7214685B2 (en)	2000-05-02	2007-05-08	Lutz F. Tietze	Prodrugs for a selective cancer therapy
WO2002088079A2 (en)	2001-05-01	2002-11-07	Bristol-Myers Squibb Company	Dual inhibitors of pde 7 and pde 4
WO2003030909A1 (en)	2001-09-25	2003-04-17	Bayer Pharmaceuticals Corporation	2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI330183B (pt) *	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
WO2003057689A1 (en) *	2002-01-02	2003-07-17	Fujisawa Pharmaceutical Co., Ltd.	Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
MXPA04007470A (es) *	2002-02-14	2004-11-10	Pharmacia Corp	Piridinonas sustituidas.
AU2003234628B2 (en) *	2002-05-21	2007-08-23	Amgen Inc.	Substituted heterocyclic compounds and methods of use
GB0215676D0 (en) *	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
EP1554256B1 (en)	2002-07-15	2009-12-09	Merck & Co., Inc.	Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US20050014753A1 (en)	2003-04-04	2005-01-20	Irm Llc	Novel compounds and compositions as protein kinase inhibitors
CL2004002050A1 (es) *	2003-08-13	2005-06-03	Pharmacia Corp Sa Organizada B	Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
TW200533357A (en)	2004-01-08	2005-10-16	Millennium Pharm Inc	2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
WO2005099711A1 (en)	2004-04-13	2005-10-27	Icagen, Inc.	Polycyclic pyrimidines as potassium ion channel modulators
US7429604B2 (en) *	2004-06-15	2008-09-30	Bristol Myers Squibb Company	Six-membered heterocycles useful as serine protease inhibitors
EP1786781A2 (en)	2004-08-27	2007-05-23	GPC Biotech AG	Pyrimidine derivatives
GB0420722D0 (en) *	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
GB0428514D0 (en)	2004-12-31	2005-02-09	Prosidion Ltd	Compounds
US20070078135A1 (en)	2005-04-18	2007-04-05	Neurogen Corporation	Substituted heteroaryl CB1 antagonists
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
US7572809B2 (en)	2005-12-19	2009-08-11	Hoffmann-La Roche Inc.	Isoquinoline aminopyrazole derivatives
MX2008010635A (es)	2006-02-16	2008-10-28	Schering Corp	Derivados de pirrolidina como inhibidores de cinasa regulada por señales extracelulares.
WO2007125405A2 (en)	2006-05-01	2007-11-08	Pfizer Products Inc.	Substituted 2-amino-fused heterocyclic compounds
DE102006035202A1 (de)	2006-07-29	2008-01-31	Lanxess Deutschland Gmbh	Konservierungsmittel auf Basis von Carbonsäureanhydriden
ATE530540T1 (de)	2006-08-23	2011-11-15	Pfizer Prod Inc	Pyrimidonverbindungen als gsk-3-inhibitoren
WO2008039882A1 (en)	2006-09-30	2008-04-03	Sanofi-Aventis U.S. Llc	A combination of niacin and a prostaglandin d2 receptor antagonist
JO2985B1 (ar)	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
CA2672518A1 (en)	2006-12-22	2008-07-03	Novartis Ag	Organic compounds and their uses
ATE467630T1 (de)	2007-02-01	2010-05-15	Tibotec Pharm Ltd	Verfahren und zwischenprodukte zur herstellung eines makrozyklischen proteasehemmers von hcv
KR20100020454A (ko)	2007-06-08	2010-02-22	바이엘 크롭사이언스 소시에떼아노님	살진균제 헤테로사이클릴-피리미디닐-아미노 유도체
ES2535166T3 (es)	2007-09-04	2015-05-06	The Scripps Research Institute	Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
CN101902912A (zh)	2007-11-06	2010-12-01	纳幕尔杜邦公司	杀真菌杂环胺
JP5276676B2 (ja)	2008-02-21	2013-08-28	メルク・シャープ・アンド・ドーム・コーポレーション	Ｅｒｋ阻害剤である化合物
US20090246198A1 (en)	2008-03-31	2009-10-01	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors and methods of use thereof
CA2986640C (en)	2008-06-27	2019-03-26	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
CA2729327C (en)	2008-06-27	2016-10-11	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives that modulate the activity of stearoyl-coa desaturase
US8940891B2 (en) *	2008-12-08	2015-01-27	Arena Pharmaceuticals, Inc.	Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
DE102009051799B4 (de)	2009-11-03	2021-07-01	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts	Bifunktionale Prodrugs und Drugs
DE102009060175A1 (de)	2009-12-23	2011-06-30	Merck Patent GmbH, 64293	Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
JPWO2012020786A1 (ja) *	2010-08-11	2013-10-28	日本新薬株式会社	医薬組成物
ES2543050T3 (es)	2011-02-28	2015-08-14	Array Biopharma, Inc.	Inhibidores de serina/treonina quinasa
CN102250065B (zh) *	2011-05-20	2015-05-13	浙江海正药业股份有限公司	取代的三嗪苯脲衍生物及其用途
US9187462B2 (en)	2011-08-04	2015-11-17	Array Biopharma Inc.	Substituted quinazolines as serine/threonine kinase inhibitors
AU2013225737B2 (en)	2012-03-01	2018-03-01	Array Biopharma Inc.	Serine/threonine kinase inhibitors
KR20150047597A (ko)	2012-08-27	2015-05-04	어레이 바이오파마 인크.	과증식성 질환의 치료를 위한 세린/트레오닌 키나아제 억제제
KR102244553B1 (ko)	2013-08-23	2021-04-23	가부시키가이샤 한도오따이 에네루기 켄큐쇼	용량 소자 및 반도체 장치
US9532987B2 (en) *	2013-09-05	2017-01-03	Genentech, Inc.	Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
MX370906B (es) *	2013-12-30	2020-01-09	Genentech Inc	Inhibidores de serina/treonina cinasa.
MX2016008624A (es) *	2013-12-30	2017-01-06	Genentech Inc	Inhibidores de serina/treonina cinasa.
RU2684102C2 (ru) *	2014-04-09	2019-04-04	Дженентек, Инк.	Способ получения лекарственных средств

2013
- 2013-03-01 AU AU2013225737A patent/AU2013225737B2/en active Active
- 2013-03-01 EP EP17207123.5A patent/EP3321262B1/en active Active
- 2013-03-01 WO PCT/US2013/028622 patent/WO2013130976A1/en active Application Filing
- 2013-03-01 HU HUE17207123A patent/HUE053994T2/hu unknown
- 2013-03-01 RU RU2014139601A patent/RU2650501C2/ru active
- 2013-03-01 RS RS20210252A patent/RS61500B1/sr unknown
- 2013-03-01 LT LTEP17207123.5T patent/LT3321262T/lt unknown
- 2013-03-01 HU HUE13710222A patent/HUE037423T2/hu unknown
- 2013-03-01 LT LTEP13710222.4T patent/LT2820009T/lt unknown
- 2013-03-01 MY MYPI2014702447A patent/MY191936A/en unknown
- 2013-03-01 ES ES13710222.4T patent/ES2665073T3/es active Active
- 2013-03-01 AR ARP130100671A patent/AR090220A1/es active IP Right Grant
- 2013-03-01 PH PH12015501653A patent/PH12015501653A1/en unknown
- 2013-03-01 PE PE2014001344A patent/PE20150666A1/es active IP Right Grant
- 2013-03-01 JP JP2014560091A patent/JP6068515B2/ja active Active
- 2013-03-01 SI SI201331857T patent/SI3321262T1/sl unknown
- 2013-03-01 NZ NZ700314A patent/NZ700314A/en unknown
- 2013-03-01 MX MX2014010432A patent/MX354675B/es active IP Right Grant
- 2013-03-01 PT PT172071235T patent/PT3321262T/pt unknown
- 2013-03-01 CN CN201610625941.3A patent/CN106349217B/zh active Active
- 2013-03-01 TW TW102107403A patent/TWI589569B/zh active
- 2013-03-01 DK DK17207123.5T patent/DK3321262T3/da active
- 2013-03-01 DK DK13710222.4T patent/DK2820009T3/en active
- 2013-03-01 SG SG11201405356QA patent/SG11201405356QA/en unknown
- 2013-03-01 CN CN201380022620.9A patent/CN104507926B/zh active Active
- 2013-03-01 CA CA2866086A patent/CA2866086C/en active Active
- 2013-03-01 EP EP13710222.4A patent/EP2820009B1/en active Active
- 2013-03-01 RS RS20180399A patent/RS57097B1/sr unknown
- 2013-03-01 SI SI201331002T patent/SI2820009T1/en unknown
- 2013-03-01 US US13/782,513 patent/US8697715B2/en active Active
- 2013-03-01 PL PL17207123T patent/PL3321262T3/pl unknown
- 2013-03-01 ES ES17207123T patent/ES2857649T3/es active Active
- 2013-03-01 KR KR1020147027516A patent/KR102093526B1/ko active IP Right Grant
- 2013-03-01 UA UAA201410688A patent/UA116774C2/uk unknown
- 2013-03-01 BR BR112014021634-7A patent/BR112014021634B1/pt active IP Right Grant
- 2013-03-01 PL PL13710222T patent/PL2820009T3/pl unknown
- 2013-03-01 PT PT137102224T patent/PT2820009T/pt unknown
- 2013-12-23 NO NO13811985A patent/NO2945854T3/no unknown
2014
- 2014-02-14 US US14/181,418 patent/US9259470B2/en active Active
- 2014-08-29 PH PH12014501947A patent/PH12014501947A1/en unknown
- 2014-08-29 CL CL2014002301A patent/CL2014002301A1/es unknown
- 2014-08-31 IL IL234376A patent/IL234376A/en active IP Right Grant
- 2014-09-08 CR CR20140413A patent/CR20140413A/es unknown
- 2014-09-11 ZA ZA2014/06688A patent/ZA201406688B/en unknown
- 2014-09-18 CO CO14207777A patent/CO7081155A2/es unknown
2015
- 2015-05-21 HK HK15104843.4A patent/HK1204323A1/xx unknown
- 2015-07-06 HK HK15106441.5A patent/HK1206011A1/xx unknown
- 2015-07-24 PH PH12015501654A patent/PH12015501654B1/en unknown
- 2015-09-11 JP JP2015179810A patent/JP2016027053A/ja not_active Withdrawn
- 2015-12-03 ZA ZA2015/08847A patent/ZA201508847B/en unknown
2016
- 2016-01-12 US US14/993,985 patent/US9708290B2/en active Active
- 2016-02-24 IL IL244276A patent/IL244276B/en active IP Right Grant
2017
- 2017-06-16 US US15/625,297 patent/US10519126B2/en active Active
2018
- 2018-04-13 HR HRP20180591TT patent/HRP20180591T1/hr unknown
- 2018-04-18 CY CY20181100417T patent/CY1120172T1/el unknown
- 2018-10-22 HK HK18113513.1A patent/HK1254429A1/zh unknown
2021
- 2021-03-24 HR HRP20210482TT patent/HRP20210482T1/hr unknown
- 2021-04-19 AR ARP210101043A patent/AR121879A2/es unknown

Also Published As

Publication number	Publication date
IL244276B (en)	2020-01-30
US10519126B2 (en)	2019-12-31
DK3321262T3 (da)	2021-01-25
UA116774C2 (uk)	2018-05-10
NZ700314A (en)	2016-08-26
CN106349217B (zh)	2020-08-28
CN104507926B (zh)	2016-08-31
US8697715B2 (en)	2014-04-15
ES2665073T3 (es)	2018-04-24
DK2820009T3 (en)	2018-04-16
AR090220A1 (es)	2014-10-29
HK1204323A1 (en)	2015-11-13
NO2945854T3 (pt)	2018-07-21
PH12015501653B1 (en)	2017-04-10
US20180127393A1 (en)	2018-05-10
CN106349217A (zh)	2017-01-25
RU2014139601A (ru)	2016-04-20
SG11201405356QA (en)	2014-11-27
CA2866086A1 (en)	2013-09-06
CL2014002301A1 (es)	2015-05-08
LT3321262T (lt)	2021-06-10
PH12014501947B1 (en)	2014-11-24
MX2014010432A (es)	2015-02-04
PH12014501947A1 (en)	2014-11-24
AR121879A2 (es)	2022-07-20
EP3321262B1 (en)	2021-01-13
PE20150666A1 (es)	2015-05-06
KR20140138820A (ko)	2014-12-04
RS57097B1 (sr)	2018-06-29
JP6068515B2 (ja)	2017-01-25
EP2820009B1 (en)	2018-01-31
PH12015501654A1 (en)	2017-04-10
JP2015508828A (ja)	2015-03-23
TW201339146A (zh)	2013-10-01
US20130252934A1 (en)	2013-09-26
AU2013225737B2 (en)	2018-03-01
HRP20180591T1 (hr)	2018-05-18
PL2820009T3 (pl)	2018-09-28
ZA201406688B (en)	2017-08-30
PH12015501653A1 (en)	2017-04-10
PT2820009T (pt)	2018-04-12
BR112014021634B1 (pt)	2022-09-27
HK1206011A1 (en)	2015-12-31
WO2013130976A1 (en)	2013-09-06
RU2650501C2 (ru)	2018-04-16
ZA201508847B (en)	2023-01-25
SI2820009T1 (en)	2018-05-31
EP3321262A1 (en)	2018-05-16
LT2820009T (lt)	2018-05-10
HK1254429A1 (zh)	2019-07-19
PL3321262T3 (pl)	2021-06-28
HRP20210482T1 (hr)	2021-05-14
JP2016027053A (ja)	2016-02-18
KR102093526B1 (ko)	2020-03-25
CO7081155A2 (es)	2014-10-10
US9708290B2 (en)	2017-07-18
US9259470B2 (en)	2016-02-16
RS61500B1 (sr)	2021-03-31
CN104507926A (zh)	2015-04-08
EP2820009A1 (en)	2015-01-07
ES2857649T3 (es)	2021-09-29
IL244276A0 (en)	2016-04-21
TWI589569B (zh)	2017-07-01
CY1120172T1 (el)	2018-12-12
CA2866086C (en)	2020-06-09
US20160122316A1 (en)	2016-05-05
BR112014021634A8 (pt)	2018-01-30
CR20140413A (es)	2014-11-05
HUE053994T2 (hu)	2021-08-30
MX354675B (es)	2018-03-15
HUE037423T2 (hu)	2018-08-28
MY191936A (en)	2022-07-19
PH12015501654B1 (en)	2017-04-10
IL234376A (en)	2016-10-31
SI3321262T1 (sl)	2021-04-30
US20140249127A1 (en)	2014-09-04

Publication	Publication Date	Title
HK1254429A1 (zh)	2019-07-19	絲氨酸/蘇氨酸激酶抑制劑
IL261282A (en)	2018-10-31	Furinone compounds as kinase inhibitors
HK1210775A1 (en)	2016-05-06	Imidazotriazinecarbonitriles useful as kinase inhibitors
HK1225735A1 (zh)	2017-09-15	絲氨酸/蘇氨酸激酶抑制劑
HK1208442A1 (en)	2016-03-04	Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk
HK1223877A1 (zh)	2017-08-11	絲氨酸/蘇氨酸激酶抑制劑
HK1210174A1 (en)	2016-04-15	Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases
HK1222647A1 (zh)	2017-07-07	激酶抑制劑
IL227399A0 (en)	2013-09-30	Novel azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
HUE048834T2 (hu)	2020-08-28	Kináz inhibitorok
HK1211574A1 (en)	2016-05-27	Serine threonine kinase inhibitors
HK1211578A1 (en)	2016-05-27	Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1
GB201211310D0 (en)	2012-08-08	CSF-1R kinase inhibitors
EP2702064A4 (en)	2014-10-08	Kinase Inhibitors
ZA201604461B (en)	2022-05-25	Serine/threonine kinase inhibitors
PL2634185T3 (pl)	2016-06-30	Inhibitory kinazy TYK2
HK1199873A1 (en)	2015-07-24	Kinase inhibitors
SG11201500973WA (en)	2015-04-29	Amino-quinolines as kinase inhibitors
HK1213252A1 (zh)	2016-06-30	雙環二氫吡啶酮激酶抑制劑
HK1213181A1 (zh)	2016-06-30	雙環氧雜內酰胺激酶抑制劑